Caxton Associates LLP purchased a new position in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,948 shares of the technology company’s stock, valued at approximately $1,025,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in Novanta by 321.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,049 shares of the technology company’s stock worth $651,000 after buying an additional 3,852 shares during the period. Captrust Financial Advisors increased its position in shares of Novanta by 30.7% during the second quarter. Captrust Financial Advisors now owns 3,191 shares of the technology company’s stock worth $411,000 after acquiring an additional 750 shares in the last quarter. Wasatch Advisors LP increased its position in shares of Novanta by 10.6% during the second quarter. Wasatch Advisors LP now owns 1,100,029 shares of the technology company’s stock worth $141,827,000 after acquiring an additional 104,985 shares in the last quarter. Tidal Investments LLC raised its holdings in shares of Novanta by 15.5% during the second quarter. Tidal Investments LLC now owns 4,779 shares of the technology company’s stock worth $616,000 after acquiring an additional 640 shares during the period. Finally, Man Group plc bought a new stake in Novanta in the 2nd quarter valued at $844,000. 98.35% of the stock is currently owned by institutional investors and hedge funds.
Novanta Stock Performance
NOVT opened at $119.41 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.54 and a current ratio of 2.51. The business’s 50-day simple moving average is $113.12 and its 200 day simple moving average is $117.58. The firm has a market capitalization of $4.27 billion, a PE ratio of 81.23 and a beta of 1.59. Novanta Inc. has a 52-week low of $98.27 and a 52-week high of $173.16.
Novanta declared that its board has authorized a stock repurchase program on Thursday, September 18th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the technology company to purchase up to 4.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Zacks Research upgraded Novanta from a “strong sell” rating to a “hold” rating in a report on Monday, October 6th. Weiss Ratings downgraded Novanta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Novanta has an average rating of “Reduce” and an average price target of $133.00.
Read Our Latest Report on Novanta
About Novanta
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Recommended Stories
- Five stocks we like better than Novanta
- How to find penny stocks to invest and trade
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Dell and HP Are Raising Prices—And Investors Should Take Note
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
